RE: DSMB infoMore likely to see a clinical halt for futility for a Phase 3 trial - much larger and longer and is easier with the larger sample size to justify a halt. With the low enrollment numbers in the SCT trial spread across three dosing schedules I doubt they would halt this even if it appeared there was limited benefit. In addition, the trial was short - DSMB would not halt a trial based on results from a handful of patients - end points were 90 days. Most halts happen with trial design like tPA ( 3 hour window) or desmoteplase ( 9 hour window), which actually WAS temporarily halted in the Phase 2.